MARKET

BNTX

BNTX

BIONTECH
NASDAQ

Real-time Quotes | Nasdaq Last Sale

277.85
-3.13
-1.11%
Opening 11:48 07/23 EDT
OPEN
286.00
PREV CLOSE
280.98
HIGH
292.34
LOW
267.03
VOLUME
2.98M
TURNOVER
--
52 WEEK HIGH
283.92
52 WEEK LOW
54.10
MARKET CAP
67.11B
P/E (TTM)
51.90
1D
5D
1M
3M
1Y
5Y
U.S. not out of the woods with COVID cases rising in all 50 states, CDC head warns, urges unvaccinated to get their shots
marketwatch.com · 1h ago
Why This Company’s Covid-19 Vaccine Is Just the Beginning
Investor Place · 1h ago
Dow Jones Rallies As Snap, Twitter Jump On Earnings Beats; Chinese Stocks Plunge On Crackdown
The Dow Jones Industrial Average rallied 200 points Friday, as Snap and Twitter jumped on earnings beats. Chinese education stocks crashed.
Investor's Business Daily · 1h ago
EU Drugs Regulator Recommends Moderna Shot for Teenagers
(Bloomberg) -- European regulators cleared Moderna Inc.’s Covid-19 shot for children aged 12 to 17, offering a second weapon in the push to vaccinate teenagers on the continent as the delta variant spreads.The authorization from the European Medicines Agen...
Bloomberg · 1h ago
Fighting Infectious Diseases on the African Continent
The African continent carries a disproportionately high share of the global infectious disease burden. The extraordinary scientific progress made during the COVID-19 pandemic gives hope in addressing a range of life-threatening infectious diseases. The kEN...
GlobeNewswire · 1h ago
European agency is 1st to approve Moderna jab for children
The European Medicines Agency has recommended approving Moderna's COVID-19 vaccine for children aged 12 to 17.
The Associated Press · 1h ago
'Don’t want to get vaccinated, leave' — hedge fund founder mandates Covid shots in his office
"If somebody wants to fight me over the vaccine mandate, that's fine. Let's take it to the court," SkyBridge's Anthony Scaramucci told CNBC on Friday.
CNBC.com · 2h ago
Will I Need a Booster Shot? Here’s What We Know.
marketwatch.com · 3h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BNTX. Analyze the recent business situations of BIONTECH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BNTX stock price target is 204.07 with a high estimate of 253.10 and a low estimate of 107.60.
EPS
Institutional Holdings
Institutions: 266
Institutional Holdings: 30.08M
% Owned: 12.45%
Shares Outstanding: 241.52M
TypeInstitutionsShares
Increased
69
3.09M
New
68
9.56M
Decreased
46
2.81M
Sold Out
38
1.57M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Webull offers kinds of BioNTech SE - ADR stock information, including NASDAQ:BNTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNTX stock methods without spending real money on the virtual paper trading platform.